StockData
AC Immune SA logo

AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30
$2.13−0.01 (-0.47%)

Close on Nov 13, 2026Market cap $216.71MP/E –Yield –

AC Immune r&d expenses

Research and development expenses are spending on new products and technology.

AC Immune's R&D Expenses for the twelve months ending Dec 31, 2022 was CHF 60.34M, down 3.1% year over year. For fiscal 2025 it was CHF 56.44M, down 9.8% from the year before. Over ten years it grew 12.7% a year on average. The highest annual figure on record is CHF 62.57M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 56.44M-9.8%
FY2024Dec 31, 2024CHF 62.57M+14.6%
FY2023Dec 31, 2023CHF 54.61M-9.5%
FY2022Dec 31, 2022CHF 60.34M-3.1%
FY2021Dec 31, 2021CHF 62.28M+4.7%
FY2020Dec 31, 2020CHF 59.49M+18.0%
FY2019Dec 31, 2019CHF 50.43M+13.9%
FY2018Dec 31, 2018CHF 44.28M+35.6%
FY2017Dec 31, 2017CHF 32.66M+26.7%
FY2016Dec 31, 2016CHF 25.77M+51.2%
FY2015Dec 31, 2015CHF 17.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025CHF 16.83M+17.0%
Q2 FY2024Jun 30, 2024CHF 17.14M+9.2%
Q2 FY2023Jun 30, 2023CHF 13.68M-32.0%
Q4 FY2022Dec 31, 2022CHF 15.14M+0.1%
Q3 FY2022Sep 30, 2022CHF 14.39M+18.6%
Q2 FY2022Jun 30, 2022CHF 15.69M+35.9%
Q4 FY2021Dec 31, 2021CHF 20.12M+91.1%
Q3 FY2021Sep 30, 2021CHF 15.12M+50.1%
Q4 FY2018Dec 31, 2018CHF 12.13M+19.2%
Q3 FY2018Sep 30, 2018CHF 11.55M+40.9%
Q2 FY2018Jun 30, 2018CHF 10.53M+54.0%
Q1 FY2018Mar 31, 2018CHF 10.07M+35.1%
Q4 FY2017Dec 31, 2017CHF 10.18M–
Q3 FY2017Sep 30, 2017CHF 8.20M–
Q2 FY2017Jun 30, 2017CHF 6.84M–
Q1 FY2017Mar 31, 2017CHF 7.45M–

More AC Immune figures

See a number that looks wrong?